Multiple myeloma: Clinical practice guidelines in oncology™

Kenneth C. Anderson; Melissa Alsina; William Bensinger; J. Sybil Biermann; Asher Chanan-Khan; Raymond L. Comenzo; Carlos M. De Castro; Benjamin Djulbegovic; Sherif Farag; Carol Ann Huff; Ruby Meredith; Jeffrey Schriber; Dennis Shrieve; Seema Singhal; Mitchell R. Smith; Keith Stockerl-Goldstein; Julie M. Vose; Donna Weber; Joachim Yahalom; Furhan Yunus

doi:10.6004/jnccn.2007.0014

Multiple myeloma: Clinical practice guidelines in oncology™

Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Asher Chanan-Khan, Raymond L. Comenzo, Carlos M. De Castro, Benjamin Djulbegovic, Sherif Farag, Carol Ann Huff, Ruby Meredith, Jeffrey Schriber, Dennis Shrieve, Seema Singhal, Mitchell R. Smith, Keith Stockerl-Goldstein, Julie M. Vose, Donna Weber, Joachim Yahalom, Furhan Yunus

Hematology / Oncology / Cancer Center / Breast Clinic

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

Although multiple myeloma is sensitive to both chemotherapy and radiation therapy, it remains incurable. However, treatment algorithms (based on published data and clinical experience) can be developed to optimize therapy, which include not only therapy for the underlying disease but also supportive therapy to enhance quality of life. These guidelines prominently identify the clinical settings appropriate for treatment of patients on clinical research protocols.

Original language	English (US)
Pages (from-to)	118-147
Number of pages	30
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	5
Issue number	2
DOIs	https://doi.org/10.6004/jnccn.2007.0014
State	Published - Feb 2007

Keywords

C-reactive protein
Combination chemotherapy
Cytogenetics
Immunomodulatory drugs
Multiple myeloma
NCCN Clinical Practice Guidelines
Primary amyloidosis
Proteosome inhibitor
Stem cell transplant
Waldenström's monoclonal protein

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2007.0014

Cite this

Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Chanan-Khan, A., Comenzo, R. L., De Castro, C. M., Djulbegovic, B., Farag, S., Huff, C. A., Meredith, R., Schriber, J., Shrieve, D., Singhal, S., Smith, M. R., Stockerl-Goldstein, K., Vose, J. M., Weber, D., Yahalom, J., & Yunus, F. (2007). Multiple myeloma: Clinical practice guidelines in oncology™. JNCCN Journal of the National Comprehensive Cancer Network, 5(2), 118-147. https://doi.org/10.6004/jnccn.2007.0014

Anderson, KC, Alsina, M, Bensinger, W, Biermann, JS, Chanan-Khan, A, Comenzo, RL, De Castro, CM, Djulbegovic, B, Farag, S, Huff, CA, Meredith, R, Schriber, J, Shrieve, D, Singhal, S, Smith, MR, Stockerl-Goldstein, K, Vose, JM, Weber, D, Yahalom, J & Yunus, F 2007, 'Multiple myeloma: Clinical practice guidelines in oncology™', JNCCN Journal of the National Comprehensive Cancer Network, vol. 5, no. 2, pp. 118-147. https://doi.org/10.6004/jnccn.2007.0014

@article{923366af8cdf4cff82eef5684d737ddd,

title = "Multiple myeloma: Clinical practice guidelines in oncology{\texttrademark}",

abstract = "Although multiple myeloma is sensitive to both chemotherapy and radiation therapy, it remains incurable. However, treatment algorithms (based on published data and clinical experience) can be developed to optimize therapy, which include not only therapy for the underlying disease but also supportive therapy to enhance quality of life. These guidelines prominently identify the clinical settings appropriate for treatment of patients on clinical research protocols.",

keywords = "C-reactive protein, Combination chemotherapy, Cytogenetics, Immunomodulatory drugs, Multiple myeloma, NCCN Clinical Practice Guidelines, Primary amyloidosis, Proteosome inhibitor, Stem cell transplant, Waldenstr{\"o}m's monoclonal protein",

author = "Anderson, {Kenneth C.} and Melissa Alsina and William Bensinger and Biermann, {J. Sybil} and Asher Chanan-Khan and Comenzo, {Raymond L.} and {De Castro}, {Carlos M.} and Benjamin Djulbegovic and Sherif Farag and Huff, {Carol Ann} and Ruby Meredith and Jeffrey Schriber and Dennis Shrieve and Seema Singhal and Smith, {Mitchell R.} and Keith Stockerl-Goldstein and Vose, {Julie M.} and Donna Weber and Joachim Yahalom and Furhan Yunus",

year = "2007",

month = feb,

doi = "10.6004/jnccn.2007.0014",

language = "English (US)",

volume = "5",

pages = "118--147",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "2",

}

TY - JOUR

T1 - Multiple myeloma

T2 - Clinical practice guidelines in oncology™

AU - Anderson, Kenneth C.

AU - Alsina, Melissa

AU - Bensinger, William

AU - Biermann, J. Sybil

AU - Chanan-Khan, Asher

AU - Comenzo, Raymond L.

AU - De Castro, Carlos M.

AU - Djulbegovic, Benjamin

AU - Farag, Sherif

AU - Huff, Carol Ann

AU - Meredith, Ruby

AU - Schriber, Jeffrey

AU - Shrieve, Dennis

AU - Singhal, Seema

AU - Smith, Mitchell R.

AU - Stockerl-Goldstein, Keith

AU - Vose, Julie M.

AU - Weber, Donna

AU - Yahalom, Joachim

AU - Yunus, Furhan

PY - 2007/2

Y1 - 2007/2

N2 - Although multiple myeloma is sensitive to both chemotherapy and radiation therapy, it remains incurable. However, treatment algorithms (based on published data and clinical experience) can be developed to optimize therapy, which include not only therapy for the underlying disease but also supportive therapy to enhance quality of life. These guidelines prominently identify the clinical settings appropriate for treatment of patients on clinical research protocols.

AB - Although multiple myeloma is sensitive to both chemotherapy and radiation therapy, it remains incurable. However, treatment algorithms (based on published data and clinical experience) can be developed to optimize therapy, which include not only therapy for the underlying disease but also supportive therapy to enhance quality of life. These guidelines prominently identify the clinical settings appropriate for treatment of patients on clinical research protocols.

KW - C-reactive protein

KW - Combination chemotherapy

KW - Cytogenetics

KW - Immunomodulatory drugs

KW - Multiple myeloma

KW - NCCN Clinical Practice Guidelines

KW - Primary amyloidosis

KW - Proteosome inhibitor

KW - Stem cell transplant

KW - Waldenström's monoclonal protein

UR - http://www.scopus.com/inward/record.url?scp=33947193435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947193435&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2007.0014

DO - 10.6004/jnccn.2007.0014

M3 - Article

C2 - 17335683

AN - SCOPUS:33947193435

SN - 1540-1405

VL - 5

SP - 118

EP - 147

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 2

ER -

Multiple myeloma: Clinical practice guidelines in oncology™

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this